CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy - PubMed
7 hours ago
- #autoimmune neurological disorders
- #CAR T cell therapy
- #B cell-driven pathogenesis
- CAR T cell therapy is emerging as a promising approach for B cell-driven neurological autoimmune disorders, particularly those with pathogenic autoantibodies targeting neural structures.
- Neurological disorders discussed include neuromyelitis optica spectrum disorder, myasthenia gravis, Lambert-Eaton myasthenic syndrome, MOG antibody-associated disease, anti-NMDA receptor encephalitis, Diacylglycerol lipase alpha antibody associated encephalitis, stiff person syndrome, and multiple sclerosis.
- The article proposes a classification of CAR T cell therapies based on target antigens, including CD19/20/BCMA-directed CAR T cells, regulatory T cells modified with CARs, and chimeric autoantibody receptors (CAARs).
- Preclinical and clinical advancements, safety concerns, neurotoxicity, and the future landscape of CAR T applications in neurological disorders are discussed.
- CAR T cell therapy offers a highly specific and effective method for eliminating autoreactive B cells, potentially transforming the treatment of autoimmune neurological disorders.
- Further long-term follow-up data are needed to validate CAR T cell therapy's application in autoimmune disorders.